Raymond James Initiates Coverage On WAVE Life Sciences with Outperform Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has initiated coverage on WAVE Life Sciences (NASDAQ:WVE) with an Outperform rating and a price target of $7.
July 05, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
WAVE Life Sciences has been given an Outperform rating and a price target of $7 by Raymond James, indicating a positive outlook for the company.
The Outperform rating from Raymond James suggests that the analyst believes WAVE Life Sciences will do better than the market average or its sector. This could lead to an increase in the company's stock price in the short term. The price target of $7 also indicates that the analyst sees potential for growth in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100